BridgeBio Pharma (NASDAQ: BBIO) announced it will present data on oral infigratinib in achondroplasia at the Annual European Society for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE